At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 601 enrolled
Drug / intervention
Bepotastine Besilate Nasal Spray 2% Twice a day +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
In Brief
A Phase 2 clinical trial evaluating Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 601 participants across 1 site.
Detailed Summary
This is an efficacy study of bepotastine besilate nasal spray in seasonal allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedJan 2011
Primary CompletionFeb 2011
Study CompletionMay 2011
TodayJul 2026
First PostedJan 14, 2011
Enrollment StartDec 1, 2010
Primary CompletionFeb 1, 2011
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.5 years ago
Interventions
Bepotastine Besilate Nasal Spray 2% Twice a daydrug
nasal spray
Bepotastine Besilate Nasal Spray 3% Twice a daydrug
nasal spray
Bepotastine Besilate Nasal Spray 4% Twice a daydrug
nasal spray
Placebo Nasal Spraydrug
nasal spray